PARP inhibitors

Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Fierce Biotech
Merck KGaA
PARP inhibitors
Lynparza
Zejula
AstraZeneca
Gilead Sciences
solid tumors
Flag link:
J&J joins PARP rivals with narrow FDA clearance in prostate cancer
J&J joins PARP rivals with narrow FDA clearance in prostate cancer
BioPharma Dive
JNJ
Akeega
BRCA-mutated prostate cancer
PARP inhibitors
FDA
Flag link:
Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's rival PARP med
Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's rival PARP med
Fierce Pharma
Pfizer
FDA
prostate cancer
Talzenna
AstraZeneca
PARP inhibitors
Merck
Flag link:
J&J claims first approval for PARP combo Akeega
J&J claims first approval for PARP combo Akeega
Pharmaphorum
JNJ
Janssen
Akeega
PARP inhibitors
metastatic castration-resistant prostate cancer
Europe
Flag link:
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Fierce Biotech
Junshi Biosciences
PARP inhibitors
ovarian cancer
Merck
AstraZeneca
Lynparza
Flag link:
FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs
FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs
BioPharma Dive
Merck
AstraZeneca
Lynparza
FDA
PARP inhibitors
Flag link:
J&J wins EU backing for PARP combo Akeega in prostate cancer—but only in some patients
J&J wins EU backing for PARP combo Akeega in prostate cancer—but only in some patients
Fierce Pharma
JNJ
Akeega
prostate cancer
PARP inhibitors
Flag link:
GSK Restricts the Use of PARP Inhibitor in Ovarian Cancer at the FDA's Request
GSK Restricts the Use of PARP Inhibitor in Ovarian Cancer at the FDA's Request
BioSpace
GSK
ovarian cancer
Zejula
PARP inhibitors
FDA
Flag link:
Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
Endpoints
Pfizer
Xtandi
Talzenna
PARP inhibitors
Medivation
clinical trials
prostate cancer
Flag link:
Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor
Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor
Seeking Alpha
Merck KGaA
Nerviano Medical Sciences
NS-293
PARP inhibitors
Flag link:
ASCO-GU – prostate cancer PARPS move to the front line
ASCO-GU – prostate cancer PARPS move to the front line
EP Vantage
prostate cancer
ASCO-GU
PARP inhibitors
Lynparza
Zejula
Rubraca
Talzenna
biomarkers
AstraZeneca
Merck
GSK
JNJ
Clovis Oncology
Flag link:
AZ aims at Pfizer, GSK with potential new PARP cancer drug
AZ aims at Pfizer, GSK with potential new PARP cancer drug
Pharmaforum
AstraZeneca
PARP inhibitors
Pfizer
GSK
cancer
Lynparza
Flag link:
KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor
KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor
Fierce Biotech
KSQ Therapeutics
PARP inhibitors
ovarian cancer
breast cancer
KSQ-4279
Merck
AstraZeneca
Lynparza
Flag link:
GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker
GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker
Endpoints
GSK
Zejula
ovarian cancer
FDA
PARP inhibitors
Flag link:
Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn
Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn
Fierce Pharma
Clovis Oncology
Rubraca
NICE
UK
PARP inhibitors
Flag link:
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
Xconomy
ESMO
PARP inhibitors
prostate cancer
KRAS
Seattle Genetics
AstraZeneca
Merck
GSK
Amgen
breast cancer
Roche
Pfizer
Flag link:
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Yahoo/Reuters
GSK
AstraZeneca
ESMO
ovarianc cancer
PARP inhibitors
Lynparza
Zejula
Flag link:
AstraZeneca strengthens lead in PARP drug class
AstraZeneca strengthens lead in PARP drug class
Biopharma Dive
AstraZeneca
Merck
Lynparza
ovarian cancer
PARP inhibitors
veliparib
Flag link:
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
BioSpace
GSK
AstraZeneca
PARP inhibitors
ESMO
Lynparza
Zejula
Flag link:
ESMO 2019 preview – PARPs on parade
ESMO 2019 preview – PARPs on parade
EP Vantage
ESMO
PARP inhibitors
Lynparza
AstraZeneca
ovarian cancer
GSK
Zejula
Flag link:

Pages